These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 21497066)

  • 1. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ; Chmelařová E
    Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
    Namdari H; Tan TY; Dowzicky MJ
    Int J Infect Dis; 2012 Jan; 16(1):e60-6. PubMed ID: 22104303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci.
    Tsao SM; Lin HC; Lee CM; Hsu GJ; Chen CM; Sun W; Liu YC; Jang TN; Cheng YJ; Lu PL; Chiang PC; Wang LS; Kung HC; Chuang YC; Shi ZY; Liu JW; Huang CH; Lu CT; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S184-7. PubMed ID: 19013352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
    Garrison MW; Nuemiller JJ
    Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.
    Marco F; Dowzicky MJ
    J Glob Antimicrob Resist; 2016 Sep; 6():50-56. PubMed ID: 27530839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
    Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
    Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
    Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Denys GA; Koch KM; Dowzicky MJ
    Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE; Fritsche TR; Sader HS; Jones RN
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.